Coherus Acquires Rights from Klinge Biopharma for Eylea Biosimilar Candidate
Shots:
- Klinge will receive an up front of ~$32.5M and Coherus common stock & is also eligible to receive other regulatory and launch milestones and share profits. The transaction is expected to be completed in Q1’23
- Coherus to get an exclusive US commercialization right from Klinge Biopharma for FYB203, a biosimilar candidate to aflibercept & plans to file a BLA for FYB203 in 2023 with an expected launch in 2025 if the application is approved
- FYB203 is currently being evaluated in a P-III trial (MAGELLAN-AMD) & results are expected in the next few weeks. The therapy is also being studied in the (MAGELLAN-AMD) trial for the treatment of nAMD
Ref: Globe NewsWire | Image: Coherus
Related News:- Coherus Terminates its License Agreement with Innovent for Byvasda (biosimilar, bevacizumab)
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
